评估万古霉素联合哌拉西林-他唑巴坦在急诊严重脓毒症与脓毒性休克患者中的应用
该回顾性队列研究纳入2012至2015年342例培养阳性的严重脓毒症或脓毒性休克患者,均接受初始万古霉素联合哌拉西林-他唑巴坦治疗,评估抗菌方案 appropriateness、危险因素及结局。结果显示该联合方案对24%的患者不恰当,主要因感染非敏感病原体,尤其是ESBL菌和艰难梭菌。危险因素包括多部位感染(OR 4.383)、来自专业护理机构(OR 3.763)、COPD病史(OR 3.175)、腹腔感染(OR 2.890)和免疫抑制(OR 1.930)。未发现对死亡率的影响。作者认为,已知COPD、居住于专业护理机构、疑似艰难梭菌感染史和免疫抑制的患者可能从替代方案中获益,未来需前瞻性研究验证。
要点
- 342例急诊严重脓毒症或脓毒性休克患者中,万古霉素联合哌拉西林-他唑巴坦对24%不恰当,主要因非敏感感染(尤其ESBL菌和艰难梭菌)。
- 多部位感染(OR 4.383)、来自专业护理机构(OR 3.763)、COPD病史(OR 3.175)、腹腔感染(OR 2.890)和免疫抑制(OR 1.930)是初始方案不恰当的危险因素。
- 研究未发现初始方案不恰当对死亡率有影响。
- 作者认为,已知COPD、居住于专业护理机构、疑似艰难梭菌感染史和免疫抑制的患者可能从替代初始方案中获益。
- 未来需前瞻性研究验证这些发现。
适用人群与场景
- 2012至2015年急诊科培养阳性的严重脓毒症或脓毒性休克患者,均接受初始万古霉素联合哌拉西林-他唑巴坦治疗。
研究设计与关键结果
- 回顾性队列研究,纳入342例急诊培养阳性的严重脓毒症或脓毒性休克患者,初始接受万古霉素联合哌拉西林-他唑巴坦。
- 万古霉素联合哌拉西林-他唑巴坦对24%的患者不恰当,主要因非敏感感染,尤其ESBL菌和艰难梭菌。
- 多部位感染OR 4.383、来自专业护理机构OR 3.763、COPD病史OR 3.175、腹腔感染OR 2.890、免疫抑制OR 1.930为不恰当的危險因素。
- 未发现初始方案不恰当对死亡率有影响。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,已知COPD、居住于专业护理机构、疑似艰难梭菌感染史和免疫抑制的患者可能从替代初始经验性方案中获益。
- 未来需前瞻性研究验证这些发现。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
STUDY OBJECTIVE: To determine the frequency and cause of inadequate initial antibiotic therapy with vancomycin and piperacillin-tazobactam in patients with severe sepsis and septic shock in the emergency department (ED), characterize its impact on patient outcomes, and identify patients who would benefit from an alternative initial empiric regimen.
METHODS: Retrospective cohort study conducted between 2012 and 2015 in which 342 patients with culture-positive severe sepsis or septic shock who received initial vancomycin and piperacillin-tazobactam were reviewed to determine appropriateness of antimicrobial therapy, risk factors for inappropriate use, and outcome data. Univariate and multivariate regression analyses were determined to identify associations between inappropriate antibiotic use and outcomes and to identify risk factors that may predict which patients would benefit from an alternative initial regimen.
RESULTS: Vancomycin and piperacillin-tazobactam were inappropriate for 24% of patients with severe sepsis or septic shock, largely due to non-susceptible infections, particularly ESBL organisms and Clostridium difficile. Risk factors included multiple sources of infection (OR 4.383), admission from a skilled nursing facility (OR 3.763), a history of chronic obstructive pulmonary disease (COPD) (OR 3.175), intra-abdominal infection (OR 2.890), and immunosuppression (OR 1.930). We did not find a mortality impact.
CONCLUSION: Vancomycin and piperacillin-tazobactam were an inappropriate antibiotic combination for approximately 24% of patients with either severe sepsis or septic shock in the ED. Patients with known COPD, residence at a skilled nursing facility, a history concerning for Clostridium difficile, and immunosuppression would benefit from an alternative regimen. Future prospective studies are needed to validate these findings.
参考来源
- Le C, Chu F, Dunlay R, et al. Evaluating vancomycin and piperacillin-tazobactam in ED patients with severe sepsis and septic shock. Am J Emerg Med. 2017. PMID: 29321120. doi:10.1016/j.ajem.2017.12.055
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。